Oncology - European Medical Journal

This site is intended for healthcare professionals

Continue

Oncology

Filter
EMJ
14 Oct 2015

TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…
EMJ
14 Oct 2015

Assessing the eligibility of a breast cancer patient for genomic testing

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…
EMJ
14 Oct 2015

Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
EMJ
14 Oct 2015

Experience of the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
EMJ
15 Sep 2015

Genomic testing for breast cancer in the neoadjuvant setting

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…
EMJ
15 Sep 2015

Introducing the Oncotype DX® Breast Cancer Assay and its impact in clinical practice

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…
EMJ
15 Sep 2015

The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some…
EMJ
15 Sep 2015

Introducing the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
We’ve noticed you’re accessing
from North/South America.